Monday, August 24, 2026
← Back to archivePolicy
Policy•STAT News•Aug 24, 2026
Nurse practitioner trainees find themselves stymied by shortage of clinical mentors
background ▾
- •NP workforce growing 10% annually (2016–2023) vs. 1.1% for physicians, yet preceptor bottleneck limits training capacity and may constrain pipeline growth
- •Students paying tens of thousands out-of-pocket for required clinical placements raises ethical and equity concerns; accrediting body requirements not effectively enforced against schools
- •Monitor whether accrediting agencies strengthen enforcement, whether schools adopt systematic matching platforms (e.g., AI tools), and whether state/federal policy addresses NP workforce planning
Policy•STAT News•Aug 24, 2026
Opinion: Medicine stopped shaking hands. We should start again
background ▾
- •This is a clinical opinion/commentary piece, not news reporting on policy, trials, or market developments
Policy•STAT News•Aug 24, 2026
Opinion: I’m a retired doctor. Volunteering at a community clinic gave me an entirely new medical education
background ▾
- •The NIH enacted a stricter citizenship documentation mandate in January 2025 for campus visitors, which reduced access to free advanced cardiac imaging for uninsured trial participants—a policy change with real-world impact on vulnerable patient populations
lisinoprilsacubitril/valsartan
→ Read original articlePolicy•STAT News•Aug 24, 2026
Americans bought 12% less soda under new SNAP restrictions, study says
background ▾
- •SNAP soda restrictions achieved a 12% reduction in soda purchases among recipients, preventing an estimated 34,000 diabetes cases and saving $1 billion annually in healthcare costs—a modest but meaningful public health outcome.
- •39% of money not spent on soda was redirected to other sugary drinks and fruit juices outside the ban's scope, suggesting comprehensive restrictions would be more effective than current categorical bans.
- •The restrictions significantly increased stigma among SNAP recipients, introducing a social cost trade-off that complicates policy efficacy assessment and may not be justified given the modest national health gains for the 12% of Americans on SNAP.
Policy•KFF•Aug 21, 2026
State and Local Policies on School Vaccine Requirements: Overview and Current Status
background ▾
- •States possess constitutional authority to impose school vaccine requirements and have consistently prevailed in legal challenges; federal courts have upheld this power from Jacobson v. Massachusetts (1905) through recent 2026 appeals court rulings affirming removal of religious exemptions.
Smallpox vaccineDiphtheria vaccineTetanus vaccine
→ Read original articleMarket Access
Market Access•Fierce Biotech•Aug 21, 2026
Werewolf transforms into Ambros via reverse merger to support phase 3 push for rare disease drug
background ▾
- •Werewolf's reverse merger into Ambros with $150M financing solves an immediate capital crisis and provides runway through FDA filing for neridronate in CRPS-1, a rare pain disorder with no approved therapies.
- •Ambros is targeting a narrow, biomarker-enriched patient subpopulation (warm CRPS-1 with positive triple-phase bone scan) based on mechanistic insights from prior Italian data, potentially increasing Phase 3 success probability.
- •Phase 3 topline expected end-2027/early-2028; watch for enrollment progress, interim safety signals, and whether the biomarker-selected population achieves the 12-week pain intensity reduction endpoint required for FDA approval.
Werewolf TherapeuticsAmbros TherapeuticsRA Capital Managementneridronate
→ Read original articleMarket Access•Endpoints News•Aug 21, 2026
Chronic pain biotech co-founded by Vivek Ramaswamy joins reverse merger train
background ▾
- •Ramaswamy-co-founded chronic pain biotech pursuing reverse merger for public listing despite lacking US FDA approval
- •Drug already approved in Italy but US regulatory and market access strategy unclear
Vivek Ramaswamy's chronic pain biotech
→ Read original articleMarket Access•Endpoints News•Aug 21, 2026
Genentech invests $750M in new factory; Bavarian Nordic delays Lyme trial
background ▾
- •Genentech's $750M facility investment indicates confidence in sustained demand for advanced drug delivery platforms, likely supporting pipeline programs requiring specialized manufacturing.
GenentechRocheBavarian NordicLyme disease vaccine (Bavarian Nordic)
→ Read original articleMarket Access•Endpoints News•Aug 21, 2026
Replimune lands commercial chief after hard-fought approval; Neumora's Paul Berns sheds CEO title
background ▾
- •Replimune secured accelerated FDA approval for its melanoma therapy and is now building out commercial infrastructure with a new CCO hire
- •CCO appointment timing immediately post-approval is critical for establishing go-to-market strategy and payer negotiations for the approved indication
ReplimuneNeumora
→ Read original articleClinical Trials
Clinical Trials•Fierce Biotech•Aug 21, 2026
Why Pheast’s CEO has no regrets about transparent approach to R&D despite competitors circling
background ▾
- •PHST001 showed good tolerability and early signs of clinical activity (disease stabilization, tumor shrinkage) in phase 1a, with most adverse events grade 1-2, supporting advancement to phase 1b combination studies
- •Antengene's ATG-031 entered human trials 2 years earlier (2023 vs April 2025), demonstrating the competitive risk of transparent research approaches, though Pheast management rejects pressures toward secrecy
- •Phase 1b combination data expected in 2026 will be critical to establishing PHST001's differentiation from prior CD24/CD47 clinical stumbles and determining commercial viability in macrophage checkpoint space
Pheast TherapeuticsAntengenePHST001ATG-031
→ Read original articleClinical Trials•Endpoints News•Aug 22, 2026
Third death in China’s expedited trials; Merck and Moderna’s cancer vaccine win; and more
background ▾
- •Merck and Moderna's personalized cancer vaccine achieved positive topline results, validating the neoantigen vaccine approach in oncology
- •This represents a major partnership milestone between two major pharma/biotech companies in the high-stakes cancer immunotherapy space
- •Watch for full data publication, upcoming trial expansions, and regulatory pathway clarification (likely BLA/MAA filings)
MerckModernaPersonalized cancer vaccine (Merck/Moderna)
→ Read original article